Rezaie A R
Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City 73104, USA.
Biochemistry. 1998 Sep 22;37(38):13138-42. doi: 10.1021/bi9808518.
Plasminogen activator inhibitor-1 (PAI-1) is a serine protease inhibitor of the serpin superfamily which rapidly inactivates tissue plasminogen activator (tPA), but reacts with thrombin at a much slower rate. Based on the previous mutagenesis studies and the X-ray crystal structure of the thrombin E192Q-bovine pancreatic trypsin inhibitor (BPTI) complex, the structural basis for the slow reactivity of thrombin with PAI-1 is investigated in this study. In the crystal structure of the thrombin E192Q-BPTI complex, the reactive site loop of BPTI is stabilized in a canonical conformation by several productive interactions (e.g., Glu39 of thrombin is ion-paired to the P5' Arg, and Gln192 is hydrogen-bonded to the P2 and P4 backbone carbonyls of BPTI). PAI-1 contains Glu residues at both the P4' and P5' positions, and previous mutagenesis studies suggest that these residues make productive interactions with Arg39 of tPA as well as with two other positively charged residues present on the 39-loop of the protease (chymotrypsin numbering). Glu39 and Glu192 of thrombin would be unable to make such productive interactions with PAI-1. Instead, their repulsive interactions with the similarly charged residues and/or the backbone carbonyls of the PAI-1 reactive site loop could restrict the reaction. To test this, the rate constants (k2) for the PAI-1 inactivation of wild-type, E39K, E39Q, E192Q, E192M, and E39K/E192Q thrombins were determined. The inactivation rates of E39K [k2 = (4.3 +/- 0.2) x 10(4) M-1 s-1] and E39Q [k2 = (1.0 +/- 0.1) x 10(4) M-1 s-1] were 50- and 12-fold faster than the inactivation of wild-type thrombin [k2 = (8.6 +/- 0. 5) x 10(2) M-1 s-1], respectively. Relative to thrombin, the PAI-1 inactivation rates were improved 31-fold for E192Q [k2 = (2.7 +/- 0. 5) x 10(4) M-1 s-1] and 5-fold for E192M [k2 = (4.3 +/- 0.8) x 10(3) M-1 s-1] thrombins. With the double mutant E39K/E192Q, the inactivation rate [k2 = (5.4 +/- 0.4) x 10(5) M-1 s-1] was improved 628-fold over wild-type thrombin. These results suggest that repulsive interactions and/or lack of productive electrostatic interactions between PAI-1 and Glu39 and Glu192 of thrombin are responsible for the slow reaction of thrombin with this serpin.
纤溶酶原激活物抑制剂-1(PAI-1)是丝氨酸蛋白酶抑制剂超家族中的一种丝氨酸蛋白酶抑制剂,它能迅速使组织纤溶酶原激活物(tPA)失活,但与凝血酶的反应速率要慢得多。基于先前的诱变研究以及凝血酶E192Q-牛胰蛋白酶抑制剂(BPTI)复合物的X射线晶体结构,本研究探讨了凝血酶与PAI-1反应缓慢的结构基础。在凝血酶E192Q-BPTI复合物的晶体结构中,BPTI的反应位点环通过几种有效相互作用稳定在标准构象中(例如,凝血酶的Glu39与P5'精氨酸形成离子对,Gln192与BPTI的P2和P4主链羰基形成氢键)。PAI-1在P4'和P5'位置均含有谷氨酸残基,先前的诱变研究表明,这些残基与tPA的Arg39以及蛋白酶39环上存在的另外两个带正电荷的残基(胰凝乳蛋白酶编号)形成有效相互作用。凝血酶的Glu39和Glu192无法与PAI-1形成此类有效相互作用。相反,它们与PAI-1反应位点环上带相同电荷的残基和/或主链羰基的排斥相互作用可能会限制反应。为了验证这一点,测定了野生型、E39K、E39Q、E192Q、E192M和E39K/E192Q凝血酶使PAI-1失活的速率常数(k2)。E39K [k2 = (4.3 ± 0.2) x 10(4) M-1 s-1]和E39Q [k2 = (1.0 ± 0.1) x 10(4) M-1 s-1]的失活速率分别比野生型凝血酶 [k2 = (8.6 ± 0.5) x 10(2) M-1 s-1]快50倍和12倍。相对于凝血酶,E192Q [k2 = (2.7 ± 0.5) x 10(4) M-1 s-1]使PAI-1的失活速率提高了31倍,E192M [k2 = (4.3 ± 0.8) x 10(3) M-1 s-1]使PAI-1的失活速率提高了5倍。对于双突变体E39K/E192Q,失活速率 [k2 = (5.4 ± 0.4) x 10(5) M-1 s-1]比野生型凝血酶提高了628倍。这些结果表明,PAI-1与凝血酶的Glu39和Glu192之间的排斥相互作用和/或缺乏有效的静电相互作用是凝血酶与这种丝氨酸蛋白酶抑制剂反应缓慢的原因。